Skip to main content

Vikas Kundra, MD, PhD

Academic Title:


Primary Appointment:

Diagnostic Radiology and Nuclear Medicine

Administrative Title:

Chief of Oncologic Imaging

Additional Title:

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center Program in Oncology, Experimental Therapeutics

Education and Training

1984-1987  B.S. Biology, Loyola University Maryland (Summa Cum Laude)
1988-1995  M.D. with Honors in a Special Field, Harvard Medical School, Harvard University, Ph.D., Program in Cell and Developmental Biology, Harvard Medical School, Harvard University, Thesis Advisor – Bruce Zetter, Ph.D., “Signal Transduction Pathways Involved in Platelet Derived Growth Factor-BB Mediated Chemotaxis”

1995-1996   Research Fellowship, Department of Radiology, Brigham and Women's Hospital
1996-2000   Clinical and Research Residency, Department of Radiology, Brigham and Women's Hospital
2000-2001   Clinical and Research Fellowship, Department of Radiology, Brigham and Women's Hospital


Dr. Kundra’s clinical activities focus on abdominal imaging, particularly CT and MR. He spends a good portion of his time in research-related activities and has received federal, institutional, and industry funding since 2003. A principal area of interest is deploying imaging methods to personalize nanoparticle chemotherapy. He holds several patents, issued and pending, in the United States and abroad for somatostatin receptor-based imaging and therapy, including for imaging of delivered gene expression with applications such as in gene and cellular therapy. He is the coauthor of over 100 peer reviewed original research publications. Recently Dr. Kundra was awarded a five year ~$3.1 million RO1 grant from the National Cancer Institute for "Multimodal Imaging and Therapy of Ovarian Cancer." He and his team will test the accuracy of proposed methods for detecting ovarian tumor implants and hypothesize that pre-surgical MR imaging and surgical optical imaging/photodestruction employing DM-Dual-Gd-based nanoparticles can improve overall survival. This proposal seeks to create a new paradigm for approaching ovarian cancer that enables presurgical planning, surgical resection, and tumor photodestruction after a single nanoparticle injection.